Loading
A phase 2 trial of BL-M07D1 in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer is a phase 2 interventional study registered as NCT07678957 by Sichuan Baili Pharmaceutical Co., Ltd., with 120 participants planned, started 2026-08-31 and due to reach its primary completion in 2028-12. Interventions recorded: BL-M07D1 and DS-8201.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares SystImmune / Sichuan Biokin, HER2-positive breast cancer and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/